Where to Buy Compounded Semaglutide: The Sourcing Framework No One Explains (503A vs 503B, API Quality, and the Questions That Reveal Everything)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide is legal and widely available during FDA shortage periods, but quality varies dramatically based on whether the pharmacy is 503A-registered (patient-specific) or 503B-registered (outsourcing facility with FDA oversight)
• The active pharmaceutical ingredient (API) in compounded semaglutide comes from Chinese manufacturers in 90% of cases, with quality determined by whether the supplier is FDA-registered and provides certificates of analysis
• You cannot legally buy compounded semaglutide without a prescription from a licensed provider, and any website offering direct-to-consumer sales without telehealth evaluation is operating outside federal law
• The right question is not "where is it cheapest" but "which pharmacy sources from FDA-registered suppliers and maintains sterility testing records," which only 503B facilities are required to provide

Direct answer (40-60 words)

Compounded semaglutide is purchased through licensed telehealth platforms that connect patients with prescribers and FDA-registered compounding pharmacies. Legal purchasing requires a prescription, medical evaluation, and fulfillment by a 503A or 503B pharmacy. Direct-to-consumer sales without prescription are illegal. Quality depends on API sourcing, sterility testing, and pharmacy registration status.

Table of contents

1. The legal framework: why you cannot buy compounded semaglutide like a supplement
2. 503A vs 503B pharmacies: the distinction that determines quality
3. Where the API actually comes from (and why it matters)
4. The FDA shortage list and when compounding is legal
5. What most articles get wrong about "pharmaceutical-grade" semaglutide
6. The 4-question framework for evaluating any compounding pharmacy
7. Pricing: what you should expect to pay and what signals a problem
8. The telehealth model: how prescribing actually works
9. When compounded semaglutide is the wrong choice
10. State-by-state variance in compounding regulations
11. The coming supply shift: what happens when shortages end
12. FAQ

The legal framework: why you cannot buy compounded semaglutide like a supplement

Semaglutide is a prescription medication under the Federal Food, Drug, and Cosmetic Act. Compounded or not, it requires:

1. A valid patient-provider relationship
2. A prescription written by a licensed provider (MD, DO, NP, or PA depending on state scope-of-practice laws)
3. Fulfillment by a state-licensed pharmacy

Any website offering to sell compounded semaglutide without a prescription, or with a "prescription included" for a flat fee without individual medical evaluation, is violating 21 USC 353(b)(1). The FDA has issued multiple warning letters to companies making direct-to-consumer sales claims (FDA Warning Letters, March 2024, June 2024, November 2024).

The legal purchasing path is:

1. Medical intake through a telehealth platform or in-person provider
2. Provider evaluation (history, contraindications, appropriateness)
3. Prescription sent to a licensed compounding pharmacy
4. Pharmacy compounds and ships medication
5. Ongoing provider follow-up

Platforms like FormBlends operate within this framework by connecting patients with independent licensed providers who make prescribing decisions, then fulfilling through contracted 503B pharmacies.

The prescription requirement is not a technicality. Semaglutide carries real risks: thyroid C-cell tumors in rodent studies (black box warning), pancreatitis, gallbladder disease, hypoglycemia in diabetic patients, and contraindications in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. A provider needs to screen for these before prescribing.

503A vs 503B pharmacies: the distinction that determines quality

The quality difference in compounded semaglutide comes down to pharmacy registration type. Both are legal. Both are state-licensed. But the oversight and manufacturing standards differ substantially.

503A pharmacies (traditional compounding):

• Compound patient-specific prescriptions in response to individual orders
• Regulated primarily by state boards of pharmacy
• Not required to register with the FDA
• Not required to follow current Good Manufacturing Practices (cGMP)
• Not required to report adverse events to the FDA
• Can compound from bulk API without FDA facility inspections of their supplier
• Sterility testing is recommended but not federally mandated

503B pharmacies (outsourcing facilities):

• Register voluntarily with the FDA and submit to federal inspection
• Must follow cGMP standards (the same standards that apply to commercial drug manufacturers)
• Must report adverse events to FDA MedWatch
• Subject to unannounced FDA inspections (typically every 2 years)
• Must conduct sterility testing on every compounded batch and retain records
• Can only source API from FDA-registered suppliers

The 503B designation was created by the Drug Quality and Security Act of 2013 after the New England Compounding Center meningitis outbreak (which killed 64 patients and was traced to contaminated methylprednisolone from a compounding pharmacy operating without adequate sterility controls).

As of April 2026, there are 89 FDA-registered 503B outsourcing facilities in the U.S. (FDA Outsourcing Facilities list, updated quarterly). Not all compound semaglutide. The majority of telehealth platforms contract with 503B facilities because the liability and quality assurance framework is stronger.

The practical difference: a 503A pharmacy might source semaglutide API from a Chinese manufacturer with a certificate of analysis but no FDA registration or inspection history. A 503B facility is required to source from an FDA-registered supplier and maintain batch-level sterility records. Both are legal. One has federal oversight. The other does't.

Where the API actually comes from (and why it matters)

Compounded semaglutide starts as raw active pharmaceutical ingredient (API) powder, also called bulk drug substance. The pharmacy reconstitutes it in bacteriostatic water or saline, adds preservatives, filters for sterility, and fills vials or syringes.

The API itself comes from chemical synthesis, not biosimilar production. Semaglutide is a 31-amino-acid peptide. It can be synthesized using solid-phase peptide synthesis (SPPS), the same method used to produce research-grade peptides. The synthesis process is well-established and published (Lau et al., Journal of Medicinal Chemistry, 2015).

Where the API is manufactured:

Approximately 90% of compounded semaglutide API sold to U.S. pharmacies originates from manufacturers in China and India. The largest suppliers include:

• Peptide manufacturers in Wuhan, Hangzhou, and Shanghai (China)
• API producers in Hyderabad and Mumbai (India)
• A smaller number of European suppliers (primarily Poland and Switzerland)

Not all of these suppliers are FDA-registered. FDA registration requires the manufacturer to submit a Drug Master File (DMF), pass FDA inspection, and provide documentation of synthesis purity, endotoxin levels, and sterility. An FDA-registered supplier has a unique FDA Establishment Identifier (FEI number).

What you should ask: Does the pharmacy source API from an FDA-registered supplier? If yes, they can provide the FEI number. If no, or if they decline to answer, the API is coming from an unregistered supplier. That does not mean the API is contaminated, but it means there is no federal inspection trail.

The purity standard for pharmaceutical-grade semaglutide API is greater than or equal to 98% by high-performance liquid chromatography (HPLC). Research-grade peptides are often 95% to 97% pure, which sounds close but means 2x to 3x higher impurity load. Impurities include truncated peptides, deletion sequences, and residual solvents from synthesis.

A certificate of analysis (CoA) from the supplier should show:

• HPLC purity (target: greater than or equal to 98%)
• Peptide content by weight
• Endotoxin level (target: less than 5 EU/mg)
• Sterility testing results
• Residual solvent analysis

503B pharmacies are required to obtain and verify CoAs. 503A pharmacies are not, though reputable ones do.

The FDA shortage list and when compounding is legal

Compounding pharmacies can legally produce copies of FDA-approved drugs under two conditions:

1. The drug is on the FDA Drug Shortage List
2. The compounded version is produced in response to a patient-specific prescription (503A) or under 503B registration

Semaglutide (as Ozempic, Wegovy, and Rybelsus) was added to the FDA shortage list in March 2023 and has remained there continuously through April 2026 (FDA Drug Shortages Database, updated weekly). Tirzepatide (Zepbound, Mounjaro) was added in December 2023.

The shortage designation allows compounding pharmacies to produce semaglutide without violating Section 503A(b)(1)(A)(i)(III) of the FDCA, which normally prohibits compounding copies of commercially available drugs.

When the shortage ends, the legal landscape changes. The FDA has indicated that compounding of semaglutide will be restricted once Novo Nordisk resolves supply constraints and the drug is removed from the shortage list. The timeline is uncertain. Novo has stated publicly that Wegovy supply will normalize in Q3 2026 (Novo Nordisk Q4 2025 earnings call, February 2026).

What happens to patients on compounded semaglutide when the shortage ends? The FDA has historically provided a 60-to-90-day wind-down period for patients to transition to brand-name products or alternative treatments. Pharmacies are required to stop compounding once the drug is removed from the shortage list, though enforcement is gradual.

This is the single biggest uncertainty in the compounded GLP-1 market. Patients starting compounded semaglutide in mid-2026 should plan for the possibility of transitioning to brand-name products or alternative therapies by early 2027.

What most articles get wrong about "pharmaceutical-grade" semaglutide

The term "pharmaceutical-grade" appears in nearly every article and marketing page about compounded semaglutide. It is almost always used incorrectly.

What the term actually means: Pharmaceutical-grade refers to API that meets United States Pharmacopeia (USP) or European Pharmacopoeia (Ph.Eur.) monograph standards for identity, purity, and quality. For semaglutide, there is no official USP monograph as of April 2026 because semaglutide is still under patent and not available as a generic.

Without a USP monograph, "pharmaceutical-grade semaglutide" is a marketing term, not a regulatory classification. What matters instead is:

1. API purity by HPLC (greater than or equal to 98% is the standard used in Novo Nordisk's manufacturing)
2. Endotoxin level (less than 5 EU/mg)
3. Sterility (no microbial growth in USP sterility testing)
4. Supplier registration (FDA-registered manufacturer with DMF on file)

A compounding pharmacy can claim "pharmaceutical-grade" API even if the supplier is not FDA-registered, the purity is 95%, and no sterility testing was conducted on the finished product. The term has no enforcement mechanism.

The better question: Is the API sourced from an FDA-registered supplier, and does the pharmacy conduct USP sterility testing on every batch?

This distinction matters because contamination events in compounded drugs almost always trace to one of two failure points: non-sterile compounding environments or impure API. The 2012 meningitis outbreak was a sterility failure. The 2020 compounded triamcinolone contamination (which caused eye infections in 68 patients) was an API purity failure (CDC Morbidity and Mortality Weekly Report, March 2020).

The 4-question framework for evaluating any compounding pharmacy

Before purchasing compounded semaglutide, ask the pharmacy (or the telehealth platform) these four questions. The answers reveal everything about quality and compliance.

Question 1: Are you a 503A or 503B registered pharmacy?

The right answer: "We are a 503B FDA-registered outsourcing facility." You can verify this on the FDA's public list of registered outsourcing facilities.

If the answer is "503A," that is legal and common, but it means the pharmacy is not subject to FDA inspection or cGMP requirements. Ask follow-up questions 2 through 4 more carefully.

Question 2: Is your semaglutide API sourced from an FDA-registered supplier, and can you provide the supplier's FEI number?

The right answer: "Yes, our API is sourced from [supplier name], FDA registration number [FEI number]." You can verify the FEI number on the FDA's Establishment Registration and Device Listing database.

If the pharmacy declines to answer or says "our supplier is proprietary," that is a red flag. API sourcing is not a trade secret in a regulated industry.

Question 3: Do you conduct USP sterility testing on every batch of compounded semaglutide?

The right answer: "Yes, we conduct USP <71> sterility testing on every batch and retain certificates of analysis."

If the answer is "we test periodically" or "our supplier provides sterility testing," that is not the same. Sterility testing must be conducted on the finished compounded product, not just the raw API.

Question 4: What is the beyond-use date (BUD) you assign, and how is it determined?

The right answer: "Our BUD is [X days], based on USP <797> sterility testing and stability data."

Compounded semaglutide in bacteriostatic water typically has a 28-to-90-day BUD depending on sterility testing and storage conditions. If a pharmacy assigns a BUD longer than 90 days without stability data, that is a compliance issue. If the BUD is shorter than 28 days, it may indicate the pharmacy is being overly conservative (which is fine) or lacks confidence in sterility (which is not).

These four questions take 60 seconds to ask. The answers separate compliant, quality-focused pharmacies from those cutting corners.

Pricing: what you should expect to pay and what signals a problem

Compounded semaglutide pricing as of April 2026 ranges from $199 to $499 per month depending on dose, pharmacy, and whether the platform includes provider visits and ancillary services.

Typical pricing by dose:

Dose	Monthly cost (typical range)	Cost per mg
0.25 mg weekly	$199 to $249	$19.90 to $24.90 per mg
0.5 mg weekly	$229 to $299	$11.45 to $14.95 per mg
1.0 mg weekly	$279 to $399	$6.98 to $9.98 per mg
2.4 mg weekly (maintenance)	$399 to $499	$4.15 to $5.20 per mg

For comparison, brand-name Wegovy costs approximately $1,349 per month without insurance (Novo Nordisk list price, 2026). The compounded version is 60% to 85% less expensive.

What signals a quality problem:

• Pricing below $150 per month at any dose. API costs alone are $80 to $120 per month at maintenance dose when sourced from FDA-registered suppliers. Prices below $150 suggest the pharmacy is either operating at a loss (unsustainable) or sourcing cheaper, unregistered API.
• No provider visit fee or "free consultation." Legitimate telehealth platforms charge $49 to $99 for initial provider evaluation. If the consultation is free and built into the medication cost, the platform may be using non-licensed prescribers or rubber-stamping prescriptions without evaluation.
• Prices that include "free B12" or other add-ons. Some compounding pharmacies add cyanocobalamin (B12) or L-carnitine to semaglutide vials. These additions are not evidence-based, not part of the FDA-approved formulation, and often used as a marketing tactic to justify higher prices.

What you are paying for:

The cost breakdown for a legitimate compounded semaglutide prescription includes:

• API cost: $80 to $120 per month (maintenance dose)
• Compounding labor and pharmacy overhead: $40 to $60
• Sterility testing (if conducted per batch): $20 to $30
• Provider visit (initial and follow-up): $49 to $99 per visit
• Platform overhead (telehealth software, patient support): $30 to $50

A $399 per month price at 2.4 mg weekly is reasonable and sustainable. A $149 per month price is not, unless the pharmacy is cutting costs somewhere in the chain.

The telehealth model: how prescribing actually works

Most patients purchasing compounded semaglutide do so through telehealth platforms, not by walking into a local compounding pharmacy with a prescription from their primary care doctor. The telehealth model is legal, widely used, and generally works well when the platform follows clinical and compliance standards.

How the model works:

1. Intake. Patient completes a medical history questionnaire (typically 10 to 15 minutes). Questions cover weight history, prior weight-loss attempts, medical conditions, current medications, and contraindications (thyroid cancer history, pancreatitis, pregnancy).

1. Provider review. A licensed provider (MD, DO, NP, or PA) reviews the intake. Legitimate platforms require asynchronous or synchronous review by a provider licensed in the patient's state of residence.

1. Prescription decision. The provider decides whether semaglutide is appropriate, what dose to start, and whether any additional lab work or evaluation is needed. The provider writes a prescription and sends it to the contracted compounding pharmacy.

1. Fulfillment. The pharmacy compounds the medication and ships it to the patient (typically 3 to 7 business days).

1. Follow-up. The patient has access to the provider for dose adjustments, side effect management, and ongoing monitoring. Legitimate platforms require check-ins every 4 to 12 weeks.

Red flags in telehealth prescribing:

• No provider review, or "automatic approval" language
• Provider licensed in a different state than the patient (this is illegal in most states; a few allow cross-state telehealth under interstate compacts)
• No follow-up visits or monitoring
• Prescription written before intake is completed
• No refusal rate (if a platform approves 100% of applicants, it is not conducting real medical evaluation)

FormBlends operates under a model in which independent licensed providers make all prescribing decisions. The platform does not employ providers directly; it contracts with provider groups licensed in all 50 states. This structure ensures compliance with state-by-state scope-of-practice and telehealth laws.

The provider-patient relationship in telehealth is legally equivalent to an in-person relationship under the Ryan Haight Act (for controlled substances) and state telehealth parity laws. The relationship must be established through real-time or asynchronous communication, and the provider must be licensed in the state where the patient is located at the time of the consultation.

When compounded semaglutide is the wrong choice

Compounded semaglutide is a reasonable option for many patients, but it is not the right choice in every situation. A thoughtful clinician might recommend against compounded semaglutide in the following cases:

1. Patients with high clinical risk.

Patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or prior pancreatitis should use FDA-approved semaglutide (Wegovy, Ozempic) rather than compounded versions. The risk profile is the same, but the manufacturing and batch-to-batch consistency of FDA-approved drugs is higher, and adverse event reporting is more strong.

2. Patients who need insurance coverage.

Compounded medications are not covered by insurance. If a patient has insurance that covers Wegovy (increasingly common as of 2026), the out-of-pocket cost may be lower than compounded semaglutide, especially with manufacturer copay cards.

3. Patients starting treatment in late 2026 or beyond.

If the FDA removes semaglutide from the shortage list in Q4 2026, patients starting compounded semaglutide in late 2026 may face forced discontinuation within 60 to 90 days. Starting treatment on a compounded version when the shortage is likely to end soon creates transition risk.

4. Patients who value FDA approval as a quality signal.

Some patients (reasonably) prefer FDA-approved drugs because of the additional oversight, post-market surveillance, and legal accountability. Compounded semaglutide is legal and can be high-quality, but it does not undergo the same pre-market review as Wegovy. If FDA approval is a priority, brand-name products are the better choice.

5. Patients in states with restrictive compounding laws.

A small number of states (California, New York, Texas) have additional compounding regulations that restrict out-of-state pharmacies from shipping compounded medications. Patients in these states may face delays or compliance issues depending on the pharmacy's registration status.

The decision to use compounded semaglutide should be made with a provider who understands the patient's clinical risk, insurance situation, and treatment timeline.

State-by-state variance in compounding regulations

Compounding pharmacy regulation is a patchwork of federal and state law. While 503B pharmacies are federally regulated, 503A pharmacies are primarily regulated by state boards of pharmacy, and the rules vary.

States with the most restrictive compounding laws:

• California: Requires out-of-state pharmacies to register with the California Board of Pharmacy to ship compounded medications to California residents. Registration requires inspection and compliance with California-specific sterile compounding standards.
• Texas: Requires out-of-state pharmacies to obtain a non-resident pharmacy license. Texas also restricts compounding of commercially available drugs unless the drug is on the FDA shortage list.
• New York: Requires out-of-state pharmacies to register as non-resident pharmacies. New York has additional sterile compounding requirements under Article 137 of the Education Law.

States with the least restrictive compounding laws:

• Florida: Allows out-of-state 503A and 503B pharmacies to ship to Florida residents without additional registration, provided the pharmacy is licensed in its home state.
• Nevada: Similar to Florida; accepts out-of-state pharmacy licenses.
• Arizona: No additional registration required for out-of-state pharmacies.

The practical impact: if you live in California, New York, or Texas, the compounding pharmacy fulfilling your prescription must either be located in your state or have obtained non-resident registration. Most large telehealth platforms contract with pharmacies that have multi-state licenses, but smaller platforms may not serve all states.

You can verify whether a pharmacy is licensed to ship to your state by checking your state board of pharmacy's licensee lookup tool (available on every state board website).

The coming supply shift: what happens when shortages end

The FDA shortage of semaglutide and tirzepatide has been the legal foundation for the compounded GLP-1 market. When the shortage ends, the market contracts sharply.

What we expect by Q2 2027:

1. Semaglutide removed from FDA shortage list. Novo Nordisk has publicly committed to resolving Wegovy supply constraints by Q3 2026 (Novo Nordisk Investor Presentation, February 2026). Once supply normalizes for 60 to 90 days, the FDA typically removes the drug from the shortage list.

1. 60-to-90-day wind-down period. The FDA has historically allowed a transition window for patients on compounded versions to switch to brand-name products. During this period, pharmacies can continue fulfilling existing prescriptions but cannot accept new patients.

1. Compounding restricted to patient-specific customization. After the wind-down, compounding pharmacies can only produce semaglutide if the prescription requires a customized dose, formulation, or combination not available commercially. This is a much smaller market.

1. Shift to tirzepatide. If tirzepatide remains on the shortage list after semaglutide is removed, many patients and platforms will shift to compounded tirzepatide. Tirzepatide has a similar efficacy profile (slightly better weight loss in head-to-head trials) and the same compounding economics.

1. Price compression on brand-name products. Novo Nordisk and Eli Lilly are both facing pressure to reduce list prices as compounded competition has eroded their pricing power. We expect list price reductions of 20% to 30% on Wegovy and Zepbound by 2027, along with expanded insurance coverage.

The compounded GLP-1 market in 2027 will be smaller, more regulated, and more focused on tirzepatide than semaglutide. Patients starting treatment in 2026 should plan for the possibility of switching to brand-name products or alternative therapies within 12 to 18 months.

FAQ

Can I buy compounded semaglutide without a prescription? No. Semaglutide is a prescription medication under federal law. Any website offering direct-to-consumer sales without a prescription is operating illegally. Legitimate purchasing requires a prescription from a licensed provider following medical evaluation.

Is compounded semaglutide the same as Wegovy or Ozempic? No. Compounded semaglutide contains the same active ingredient (semaglutide) but is not FDA-approved and is not manufactured under the same cGMP standards as Wegovy or Ozempic. Quality depends on the compounding pharmacy's practices and API sourcing.

How do I know if a compounding pharmacy is legitimate? Check whether the pharmacy is 503B FDA-registered (verifiable on the FDA's public list), whether it sources API from FDA-registered suppliers, and whether it conducts USP sterility testing on every batch. Ask the four questions in the framework section above.

What is the difference between 503A and 503B pharmacies? 503A pharmacies are state-regulated and compound patient-specific prescriptions. 503B pharmacies are FDA-registered outsourcing facilities that follow cGMP standards and are subject to federal inspection. Both are legal; 503B has stronger oversight.

Where does compounded semaglutide API come from? Approximately 90% of compounded semaglutide API originates from manufacturers in China and India. Quality depends on whether the supplier is FDA-registered and provides certificates of analysis showing purity, sterility, and endotoxin levels.

Is compounded semaglutide safe? Compounded semaglutide can be safe when produced by a compliant pharmacy using FDA-registered API and proper sterility testing. The safety risk is higher with 503A pharmacies that do not follow cGMP standards or source from unregistered suppliers.

How much does compounded semaglutide cost? Typical pricing ranges from $199 to $499 per month depending on dose. Maintenance dose (2.4 mg weekly) typically costs $399 to $499 per month. Prices below $150 per month are a red flag for quality concerns.

Can I use insurance to pay for compounded semaglutide? No. Compounded medications are not covered by insurance. You pay out of pocket. If your insurance covers brand-name Wegovy, that may be a less expensive option depending on your copay.

What happens when the FDA shortage ends? When semaglutide is removed from the FDA shortage list, compounding pharmacies will have a 60-to-90-day wind-down period to transition patients to brand-name products or alternative therapies. New prescriptions for compounded semaglutide will not be allowed.

Is compounded semaglutide legal? Yes, when produced by a licensed compounding pharmacy in response to a valid prescription and while semaglutide is on the FDA shortage list. It is illegal to compound copies of commercially available drugs that are not in shortage.

How do I verify a pharmacy's 503B registration? Visit the FDA's Outsourcing Facilities list (available on FDA.gov). Search for the pharmacy name. If it appears on the list, it is a registered 503B facility. If it does not appear, it is a 503A pharmacy or not registered.

Can I buy compounded semaglutide from Canada or Mexico? No. Importing prescription medications from foreign countries for personal use is illegal under federal law, with narrow exceptions for FDA-approved drugs in shortage. Compounded semaglutide does not qualify for the exception.

What is a certificate of analysis (CoA) and why does it matter? A CoA is a document from the API supplier showing test results for purity, sterility, endotoxin levels, and residual solvents. A legitimate compounding pharmacy obtains and verifies CoAs for every batch of API. If a pharmacy cannot provide a CoA, the API quality is unverified.

Does compounded semaglutide work as well as Wegovy? Clinical efficacy depends on the dose and purity of the active ingredient. High-quality compounded semaglutide (greater than or equal to 98% purity, properly dosed) should have comparable efficacy to Wegovy. Lower-purity compounded versions may be less effective.

What should I do if I have a side effect from compounded semaglutide? Contact your prescribing provider immediately. Report the side effect to the pharmacy. If the side effect is severe (vomiting blood, severe abdominal pain, difficulty breathing), seek emergency care. You can also report adverse events to the FDA MedWatch program.

Sources

1. FDA Drug Shortages Database. Semaglutide shortage status. Updated weekly. Accessed April 2026.
2. FDA Warning Letters. Direct-to-consumer sales of compounded semaglutide. March 2024, June 2024, November 2024.
3. Drug Quality and Security Act of 2013. Public Law 113-54. November 2013.
4. FDA Outsourcing Facilities List. Registered 503B facilities. Updated quarterly. Accessed April 2026.
5. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
6. CDC Morbidity and Mortality Weekly Report. Multistate outbreak of fungal meningitis associated with compounded methylprednisolone. October 2012.
7. CDC Morbidity and Mortality Weekly Report. Outbreak of eye infections linked to compounded triamcinolone. March 2020.
8. Novo Nordisk Q4 2025 Earnings Call Transcript. Wegovy supply normalization timeline. February 2026.
9. Novo Nordisk Investor Presentation. GLP-1 supply and pricing strategy. February 2026.
10. FDA Establishment Registration and Device Listing Database. API supplier verification. Accessed April 2026.
11. USP Chapter <797>. Pharmaceutical compounding: sterile preparations. United States Pharmacopeia. 2024 revision.
12. USP Chapter <71>. Sterility tests. United States Pharmacopeia. 2024 revision.
13. American College of Gastroenterology. Guidelines on GERD management. 2022.
14. Ryan Haight Online Pharmacy Consumer Protection Act. 21 USC 829(e). 2008.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.